IntegraGen presented data at the 60th Annual meeting of the American Academy of Child & Adolescent Psychiatry in Orlando, Florida reporting on the identification of over 1,500 genetic variants associated with autism.
The results of this study will be used to develop a new, broader version of the ARISk Test which will be designed to identify the risk of autism in children with signs of developmental delay or autism.
Click here to view press release.
IntegraGen released financial results for the half year ending on June 30, 2013. Revenue grew by 18% compared to the first half of 2012.
Click here to view press release
IntegraGen has obtained exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA which predicts progression free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy.
Click here to view press release
IntegraGen presented results on the company's latest research related to use of its proprietary microRNA biomarker to predict response to anti-EGFR therapy in KRAS wild-type metastatic colorectal cancer patients.
1. "Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastric colorectal cancer"
2. "Hsa-miR-31-3p effects on gene expression in colorectal cell lines and patients"
Lab21 and IntegraGen partner to develop new colorectal cancer diagnostic
Cambridge,UK –22nd February 2013 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.
see more >
IntegraGen announced today the formation of a Community Advisory Panel to provide the company with insight and feedback on planned educational materials and informational programs directed towards the autism community.
A new publication entitled "Parental Interest in a Genetic Risk Assessment Test for Autism Spectrum Disorders," has been published online in the journal of Clinical Pediatrics.
The Knights of Columbus Developmental Center at SSM Cardinal Glennon Children's Medical Center in St. Louis, Missouri is conducting a study with the ARISk Test.
IntegraGen announced that the company has received €2 millions in financing from funds managed by A Plus Finance. The funds will be used to support the company's efforts with biomarker development for colorectal and liver cancer and develop/commercialization efforts in the field of autism molecular diagnostics.
IntegraGen announced today the presentation of scientific data which demonstrates the role of common genetic variants towards the identification of risk of autism in siblings of children diagnosed with autism spectrum disorders during the 2012 International Meeting for Autism Research.
IntegraGen announced today financial results for the year ending December 31, 2011.
IntegraGen, Inc. Names Michael Dresner National Sales Director
Cambridge, MA (April 17, 2012) - IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, has named Michael E. Dresner National Sales Director. He will be responsible for IntegraGen's sales efforts in the U.S. associated with the ARISk™ Autism Risk Assessment Test.